TAK-577-4005: Estimating Risk of Selected Adverse Events in Patients with Von Willebrand Disease Treated With VEYVONDI® (Vonicog Alfa; Recombinant Von Willebrand Factor)

03/03/2022
02/07/2024
EU PAS number:
EUPAS45617
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

tak-577-4005-protocol-original_redact

English (1.24 MB - PDF) View document
Updated protocol

TAK-577-4005-clinical-study-protocol-redact.pdf

First published: 07/05/2024
English (1.48 MB - PDF) View document
Study results
Study report
Study report

TAK-577-4005-clinical-study-report-redact.pdf

English (914.97 KB - PDF) View document
Other information